Organovo Holdings Inc Share Price Nyse
Equities
US68620A1043
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 | 4L 3.08Cr | Sales 2025 * | 4L 3.7Cr | Capitalization | 1.17Cr 98Cr |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 | 27.9 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 26.4 x |
P/E ratio 2024 |
-0.52
x | P/E ratio 2025 * |
-0.73
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.52% |
Managers | Title | Age | Since |
---|---|---|---|
Keith Murphy
CEO | Chief Executive Officer | 52 | 01/07/01 |
Thomas Hess
DFI | Director of Finance/CFO | 60 | 01/21/01 |
Steve Kunszabo
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Adam Stern
BRD | Director/Board Member | 60 | 01/12/01 |
Keith Murphy
CEO | Chief Executive Officer | 52 | 01/07/01 |
David Gobel
BRD | Director/Board Member | 71 | 15/20/15 |
1st Jan change | Capi. | |
---|---|---|
+44.48% | 5.51TCr | |
-0.86% | 4.18TCr | |
+44.19% | 4.02TCr | |
-7.59% | 2.82TCr | |
+12.30% | 2.63TCr | |
-21.83% | 1.89TCr | |
+7.15% | 1.3TCr | |
+29.40% | 1.23TCr | |
+25.15% | 1.22TCr |